Related Experiment Video

Updated: Jul 2, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy

Asfar S Azmi1, Ramzi M Mohammad

  • 1Department of Pathology, Wayne State University School of Medicine, Detroit Michigan, USA.

Journal of Cellular Physiology
|September 4, 2008
PubMed

Insights

Small-molecule inhibitors targeting anti-apoptotic Bcl-2 proteins offer a promising strategy against drug-resistant cancers. This review details their development and clinical progress.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Oncology

Background:

  • Bcl-2 family proteins are critical regulators of apoptosis and are often overexpressed in cancer cells, conferring resistance to chemotherapy.
  • Overexpression of anti-apoptotic proteins like Bcl-2, Bcl-X(L), Mcl-1, Bcl-w, and A1/Bfl1 contributes to malignant cell survival and drug resistance.

Purpose of the Study:

  • To review the current landscape of small-molecule inhibitors (SMIs) targeting anti-apoptotic Bcl-2 proteins.
  • To summarize the mode of action and developmental status of these inhibitors.

Main Methods:

  • Literature review of scientific publications and clinical trial data.
  • Analysis of small-molecule inhibitors (SMIs) targeting protein-protein interactions within the Bcl-2 family.

Main Results:

  • Significant progress has been made in identifying and synthesizing non-peptidic, cell-permeable SMIs of Bcl-2 proteins.
  • These inhibitors demonstrate potential in preclinical and clinical development for overcoming cancer cell resistance.

Conclusions:

  • Small-molecule inhibitors targeting anti-apoptotic Bcl-2 proteins represent a promising therapeutic avenue for cancer treatment.
  • Further development and clinical evaluation are ongoing for these novel anti-cancer agents.

More Related Videos

Examining BCL-2 Family Function with Large Unilamellar Vesicles08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...